Landos Biopharma, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 6.03 million compared to USD 14.86 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.93 USD | +0.58% | -.--% | +526.50% |
May. 24 | Landos Biopharma, Inc.(NasdaqCM:LABP) dropped from S&P TMI Index | CI |
May. 23 | AbbVie Completes Acquisition of Landos Biopharma | MT |
1st Jan change | Capi. | |
---|---|---|
+526.50% | 71.68M | |
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- LABP Stock
- News Landos Biopharma, Inc.
- Landos Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023